Melanie Calvert, Professor of Outcomes Methodology at BHP founder member the University of Birmingham, has been awarded the prestigious Health Assessment Lab/Medical Outcomes Trust John Ware and Alvin Tarlov Career Achievement Prize in Patient-Reported Outcomes Measures.
Only the second UK recipient of this award, Professor Calvert is Director of Birmingham Health Partners Centre for Regulatory Science and Innovation and Director of the Centre for Patient Reported Outcomes Research which aims to optimize the use of patient reported outcomes (PROs) in clinical trials and routine care, to improve service delivery, enhance patient care and outcomes and ensure that the patient perspective is at the heart of health research and healthcare decision-making. She is also theme lead for PROs research for many centres and projects based at the ITM, including the Biomedical Research Centre, Surgical Reconstruction and Microbiology Research Centre, and Trauma Management MedTech Cooperative.
Her highly cited work has informed European Society of Cardiology guidelines, NICE and EMA guidance, and she works closely with a wide range of national and international collaborators to maximise the reach, influence and impact of her research. She sits on a number of international committees leading national and international strategy for PROs research and implementation including the PROTEUS Consortium which promotes tools and resources to optimise the use of PROs in clinical trials to ensure that patients, clinicians, and other decision-makers can make the best decisions about treatment options.
Professor Calvert said: “It is a privilege to receive the prestigious Health Assessment Lab/Medical Outcomes Trust John Ware and Alvin Tarlov Career Achievement Prize which not only recognises my contribution to the field but also that of my amazing team and international collaborators, including our wonderful patient partners. I am passionate about collecting and reporting high quality PRO data that can meaningfully inform patient choices about treatments, regulatory decision making, clinical guidelines and health policy.”
Professor Subrata Ghosh, Director of the Institute of Translational Medicine, is one of three University of Birmingham Professors to be named among the UK’s most prominent biomedical and health scientists by the Academy of Medical Sciences which has announced its prestigious list of newly elected Fellows.
Professor Ghosh is joined by Christine MacArthur, Professor of Maternal and Child Epidemiology and Charles Craddock CBE, Director of the Blood and Marrow Transplant Unit and Professor of Haemato-oncology,
in a list of 50 new Fellows, representing the UK’s leading medical scientists from academia, healthcare, industry and the public service.
The Academy’s newest Fellows have been chosen for their exceptional contributions to advancing biomedical science via world-leading research discoveries, scientific communication and engagement programmes and translating scientific advances into benefits for patients and the public. They are also the only three academics from Midlands based Universities elected this year. They will be formally admitted to the Academy on 25 June 2020.
Professor Subrata Ghosh said: “I am deeply honoured to be elected as a Fellow of the Academy of Medical Science. I appreciate the research platform that has been very productive at University of Birmingham and the impact it had on the lives of patients suffering from Inflammatory Bowel Disease. I must thank our wonderful research team at the NIHR Biomedical Research Centre and our study nurses who contribute significantly to all I do.”
Speaking of her election, Professor Christine MacArthur said: “I am very pleased to receive this award and particularly delighted for the recognition it gives to research on maternal health and the problems that women can experience after childbirth. I have no doubt that this award also recognises the collaboration and support of the many colleagues that I have worked with in my time at University of Birmingham.”
Professor Charles Craddock CBE added: “It’s a huge honour and privilege to have been elected to the Academy of Medical Sciences. As a coalface blood cancer clinician and active clinical triallist I am greatly looking forward to contributing to the vital work of the Academy translating medical research into patient benefit. As an adopted Brummie I am also to advocate the strengths- and huge attendant opportunities- of the Regional Life Sciences sector in Birmingham and the Midlands”
Professor David Adams, Head of the College of Medical and Dental Sciences and Director of Birmingham Health Partners said: “I am delighted to be able to announce that three of our most distinguished academics have been elected to the Academy of Medical Sciences this year. Election to the Academy is highly competitive with only 50 new fellows elected this year from across the UK so to have 3 fellows elected from Birmingham is a tremendous accolade for the University as well as being a great personal achievement.”
Professor Sir Robert Lechler PMedSci, President of the Academy of Medical Sciences said: “I am delighted to welcome these 50 new Fellows into the Academy’s Fellowship. Each one has made their own outstanding contribution to biomedical science and together they are advancing the health of our society in the UK and internationally. Their work affects us all, from the way we keep healthy through our lifestyle, to how we are treated if we become ill, to the way we receive information about health.
“This year our new Fellows announcement happens amidst a global health crisis. Some will face the challenge of how to continue to lead on some of the most pressing health challenges our society faces beyond coronavirus, such as heart disease, diabetes or cancer. Others have joined the global research effort to tackle the coronavirus pandemic, whether that be through working out how to treat those with the virus, joining efforts to develop a vaccine, or looking to limit the impact of the pandemic more broadly on our physical and mental health.
“Never has there been a more important time to recognise and celebrate the people behind ground-breaking biomedical and health research, working harder than ever to further knowledge and protect patients and the public.
“It brings me great pleasure to congratulate the new Fellows, and see our Fellowship grow to even greater heights of evidence-based advice, leadership and expertise.”
Medical device specialists have joined together to support the supply and deployment of vital medical equipment into the healthcare system.
The aim is to support healthcare providers in ordering new devices such as ventilators, infusion pumps, dialysis and critical care equipment that is fit for purpose and appropriate for use in treating COVID-19 patients.
Activities range from sourcing suitable suppliers and devices and checking devices are compliant, through to commissioning, training, ensuring availability of replacement parts and potential ongoing maintenance. The work will include both domestic suppliers and imported equipment, striking a balance between fast access and due process to make sure vital equipment is supplied in a safe and reliable manner.
The team includes researchers from the Healthcare Technologies Institute based within the Institute of Translational Medicine, as well as staff from Hugo Technology, a medical equipment maintenance and management company and MRA Technology, a medical device consultancy.
Experts in the Healthcare Technologies Institute and at MRA Technology are working on sourcing suppliers and carrying out initial due diligence on machines, while assessment and specialist testing could then be carried out in Birmingham and at Hugo Technology.
Dr Richard Williams, from the Healthcare Technologies Institute, explains: “It’s well known that healthcare providers are in urgent need of basic medical equipment that can be supplied rapidly and in large volumes. It is so important, however, that this vital equipment will perform to the expected standard.
“We are keen to work closely with our NHS partners to find out what they need, because not all the equipment available on the market will be suitable for treating COVID-19 patients. Even in times of national emergency we need to uphold patient safety and make sure processes are in place for staff to be able to have the correct equipment to carry out their duties.”
The team has already been at work verifying ventilators and infusion devices from suppliers across the world prior to their being installed in NHS hospitals and in the new NHS Nightingale Hospital set up in London’s ExCel exhibition centre.
Dr Mark Reeves, from MRA Technology said: “Without having physically met the other team members we gravitated quickly, defined how we could best contribute to the crisis and performed tasks required according to our skills and availability at any time.”
Beyond the current pandemic, the plan is to help set in place systems and processes that are sufficiently robust to enable the NHS to respond to future emergencies.
Dr Reeves further commented: “Multidisciplinary expert teams such as ours must be front and centre when reviewing the response to this crisis and planning how to avoid equipment shortages in the inevitable future pandemics. Next time we need the time and resources to procure, hold in readiness and distribute additional complex medical equipment into whatever medical mass-emergency hits us next.”
A disposable plastic ‘pop-up tent’ which creates a protective barrier between patients and healthcare professionals could be the latest line of defence for frontline NHS workers thanks to a new product developed by a collaborative team effort in Birmingham.
Designed by experts at the University of Birmingham, the Disposable Resuscitation, Intubation and Nebulisation Kit Shield – or DRs INK Shield – is a compact device designed to cover the patient’s head, neck and shoulder area while treatments for COVID-19 are administered.
The transparent plastic shield, which features self-closing access points, protects medical staff from airborne droplets that may put them at risk of contracting the virus while allowing them line-of-sight access to the patients’ airways to perform life-saving procedures such as inserting or removing breathing tubes.
Barrier products like these already exist, however current designs are often hard walled boxes which are not only difficult to store in large numbers, but difficult to manoeuvre in emergency situations. The DRs INK Shield is around five times lighter and one third of the cost of currently available solutions.
Its pop-up design means it can be assembled in seconds as well as easy to store prior to use while the disposable material means that it can be disposed of along with other clinical waste.
The prototype was tested at the Royal Orthopaedic Hospital in Birmingham with nursing staff, recovery room technicians and anaesthetists. Medical staff using the equipment reported feeling safer and more comfortable, and that it is easy to assemble and use.
Design lead Matthew Campbell-Hill from the Institute of Clinical Sciences said: “We’re told that COVID-19 is primarily spread through respiratory secretions which transmit the virus via the fine spray of droplets released when infected people talk, cough, sneeze or even yawn.
“With much of the treatment for the virus focused around the airways, it is imperative that healthcare workers are protected from potential contamination while still being able to deliver the vital treatments that will save people’s lives.
“Our shield offers an additional form of PPE that can be rapidly assembled during emergency situations adding an extra layer of protection for frontline staff. Staff who have used it report increased confidence in their personal safety, as well as the ease of use and lightness. While this design has the potential to be a vital tool during the current pandemic, we envisage its use in a range of care settings beyond hospitals including ambulances, care homes and public areas.”
Dr Richard Williams, Research Fellow in the Healthcare Technologies Institute within the Institute of Translational Medicine added: “Taking the time to fully understand the clinical problem and then move at speed was essential. Even in this national emergency, some basic considerations of placing a product into service still apply. We drew upon our key contacts and worked remotely to provide an appropriate solution in a timely manner with the ability to scale.”
The equipment is designed to reduce exposure to COVID-19 during procedures such as intubation, resuscitation, ventilation by Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP), delivering treatments by nebuliser, and any other intervention that requires medical staff to be close to the patient’s face.
Aerosol Shield is being manufactured by Airquee, a company that makes medical, emergency and decontamination tents for the military, health services, and humanitarian organisations. The product is being sold at near-cost to healthcare providers (with a small margin to allow for any potential changes in raw material or manufacturing costs).
The next stage of the project will see the team deploy the solution as quickly as possible to the front-line of COVID-19 care. More information about the DRs INK Shield can be found on the Aerosol Shield website.
Aerosol Shield was designed by: Matthew Campbell-Hill; Dr Egidio da Silva, Consultant Anaesthetist at the Royal Orthopaedic Hospital; GP Dr Lydia Campbell-Hill; Dr Mark Reeves, Director at MRA Technology Ltd; and Dr Richard Williams. Commercial support was delivered by David Juggins from Hugo Technology Ltd, and Design Assistant Richard Baker-Stevens.
The face of trauma and emergency medicine is undeniably changing.
Between 2008 and 2017, there were almost 250,000 major trauma cases in the NHS – and the complexity of cases has increased for a number of reasons:
> Patients are getting older.
In 2008, the median age of trauma patients was 45. By 2017, it was 59. And in addition, the number of patients over the age of 65 had doubled, from 22% to 42%.
> Trauma is trickier to treat.
As a possible result of the above, trauma patients are now more likely to present with co-morbidities – existing health conditions such as diabetes, COPD, asthma or mental health problems – which may make acute trauma and injuries more difficult to treat. In 2008, only 40% of patients fell into this category – by 2017, almost two-thirds of trauma patients had one or more pre-existing health complication.
> More severe incidents are more common.
Although the median severity of injury hasn’t changed significantly, there has been a marked increase in patients with an injury severity score (ISS) of eight or more – up by 260%.
Worldwide, the picture is much the same. With road traffic increasing in developing countries, significant construction projects in countries with less stringent health and safety regulations, and human conflicts becoming more complex, global health practitioners are increasingly interested in trauma research to improve outcomes.
It’s often said that ‘war is good for medicine’ – with weaponry evolving, the types of injuries sustained by servicemen and women may never have been seen before, meaning field medical teams have to quickly develop new interventions and techniques. For example, during military operations in Iraq and Afghanistan (2003-12), survival rates for UK combat casualties improved consistently due to factors including: pre-hospital interventions during rapid transfer; more effective pre-deployment training; and enhanced protocols.
Picture shows a Medical Emergency Response Team (MERT) recovering a casualty from operations in Helmand Province, Afghanistan.
With the right teams and training in place, military medics returning to the UK now bring with them vast experience of critical, multiple injuries which they can use when treating civilian casualties. To maintain these improvements, the NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC) was established in January 2011 at the ITM – with the aims of:
Translating lessons learnt from the military to civilian practice
Designing clinical trials that can be tested in the NHS and then implemented on the battlefield
Developing innovative, holistic academic and clinical training for the leaders of the future
Facilitating engagement with industry by developing collaborative research partnerships
In addition, even when people survive trauma, the impacts are felt long after discharge. The life expectancy of trauma survivors is some ten years shorter than the general population, meaning there are potential implications for the study of ageing – and therefore the possibility of benefit for the non-trauma population too.
It’s for these reasons that SRMRC exists.
Located centrally in Birmingham, SRMRC is co-located with the Royal Centre for Defence Medicine at the renowned major trauma centre, the Queen Elizabeth Hospital. The ‘QE’ – and its parent trust University Hospitals Birmingham – is the largest teaching hospital trust in England, treating 2.2m people every year.
But more important than the size of the Trust is its depth of expertise: it is a level 1 trauma centre and receives patients from across the Midlands and further afield for emergency treatment, and its trauma team includes medics from across the armed forces.
And as part of the wider Birmingham Health Partners ecosystem, SRMRC researchers are able to collaborate with colleagues from various specialties including genomics, inflammation and ageing, metabolomics, burns research and healthcare technologies – as well as specialist clinical trials units.
The annual cost of trauma to the UK economy is some £3.8bn – but back in 2010, trauma accounted for only one per cent of research expenditure.
Now, however, with SRMRC covering trials in neurotrauma; trauma and orthopaedics; critical care; burns; hand injuries; peripheral nerve damage; and emergency and pre-hospital medicine, there is every chance that survivorship, reenablement and rehabilitation will continue to improve for both civilian and military casualties, here and overseas.
The Scar Free Foundation – based at the Institute of Translational Medicine – has won one of The Sun’s prestigious Military Awards for pioneering research carried out in partnership with Birmingham Health Partners founder members UoB and UHB, aiming to advance the rehabilitation and recovery of injured servicemen and women.
Prime Minister Boris Johnson helped hand out the awards – affectionately dubbed the Millies – which honour serving personnel and reservists for acts of sacrifice and gallantry during the past year, and pay tribute to the companies and charities that have supported the Armed Forces community.
Representatives of the Scar Free Foundation collect their trophy from Shirley Ballas and Jake Wood
The award ceremony took place at Banqueting House, Whitehall, and was attended by the Secretary of State for Defence, The Rt Hon Ben Wallace, who hosted a reception at Downing Street beforehand.
The Scar Free Foundation has always enjoyed a close relationship with the Armed Forces and veteran community and hopes its work will improve the outcomes for those injured in conflict, both now and in the future.
